Peking University Cancer Hospital & Institute
433
107
119
52
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.2%
5 terminated/withdrawn out of 433 trials
91.2%
+4.7% vs industry average
10%
43 trials in Phase 3/4
6%
3 of 52 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (433)
Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers
Role: lead
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
Role: lead
Evaluating a Text-Prompt AI Assistant for Chest CT Scans (AI-REPORT Study)
Role: collaborator
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
Role: collaborator
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
Role: collaborator
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Role: lead
Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
Role: lead
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC
Role: collaborator
Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy
Role: lead
Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency
Role: lead
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Role: collaborator
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
Role: collaborator
5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Role: lead
Clinical Application of CAIX-Targeted PET Imaging in Tumors
Role: lead
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
Role: lead
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Role: collaborator
Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
Role: lead
Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal Cancer
Role: lead
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
Role: collaborator
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Role: lead